Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy

被引:0
作者
Imai, Hisao [1 ,2 ]
Kobayashi, Daijiro [3 ]
Kaira, Kyoichi [2 ]
Kawashima, Sayaka [4 ]
Masubuchi, Ken [1 ]
Murata, Masumi [3 ]
Ebara, Takeshi [3 ,5 ]
Kitamoto, Yoshizumi [3 ]
Minato, Koichi [1 ]
机构
[1] Gunma Prefectural Canc Ctr, Div Resp Med, 617-1 Takahayashinishi, Ota, Gunma 3738550, Japan
[2] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[3] Gunma Prefectural Canc Ctr, Div Radiat Oncol, Ota, Gunma, Japan
[4] Gunma Prefectural Canc Ctr, Div Pharm, Ota, Gunma, Japan
[5] Kyorin Univ, Sch Med, Dept Radiat Oncol, Mitaka, Tokyo, Japan
关键词
chemoradiotherapy; Glasgow prognostic score; locally advanced non-small cell lung cancer; overall survival; post-progression survival; progression-free survival; GLASGOW PROGNOSTIC SCORE; SURROGATE END-POINTS; PHASE-III TRIAL; POSTPROGRESSION SURVIVAL; PERFORMANCE STATUS; TUMOR RESPONSE; CHEMOTHERAPY; THERAPY; METASTASIS; EFFICACY;
D O I
10.2478/raon-2022.0006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data. Patients and methods. Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level. Results. Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (r = 0.72, p < 0.05, R 2 = 0.54), whereas PFS was moderately correlated with OS (r = 0.58, p < 0.05, R-2 = 0.34). The Glasgow prognostic score and liver metastases at recurrence were significantly associated with PPS (p < 0.001). Conclusions. The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations
    Imai, Hisao
    Onozato, Ryoichi
    Ginnan, Maiko
    Kobayashi, Daijiro
    Kaira, Kyoichi
    Minato, Koichi
    MEDICINA-LITHUANIA, 2021, 57 (05):
  • [32] Case of post-progression prolongation of survival after cessation of pembrolizumab in advanced non-small-cell lung cancer
    Liu, Jia
    Wong, Kirby
    Patanjali, Nitya
    Boyer, Michael
    Kao, Steven
    INTERNAL MEDICINE JOURNAL, 2020, 50 (06) : 771 - 773
  • [33] Surgery for Locally Advanced and Oligometastatic Non-Small Cell Lung Cancer
    Coster, Jenalee N.
    Groth, Shawn S.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 29 (04) : 543 - 554
  • [34] Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
    Petrelli, F.
    Barni, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 186 - 192
  • [35] Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy
    Wink, Krista C. J.
    Belderbos, Jose S. A.
    Dieleman, Edith M. T.
    Rossi, Maddalena
    Rasch, Coen R. N.
    Damhuis, Ronald A. M.
    Houben, Ruud M. A.
    Troost, Esther G. C.
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 (03) : 453 - 459
  • [36] The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer
    Yosuke Miura
    Hisao Imai
    Reiko Sakurai
    Kyoichi Kaira
    Noriaki Sunaga
    Koichi Minato
    Ryusei Saito
    Takeshi Hisada
    Medical Oncology, 2018, 35
  • [37] Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients
    Liu, FangJie
    Wu, YingJia
    Shao, JianHui
    Qiu, Bo
    Guo, SuPing
    Luo, QiaoTing
    Guo, JinYu
    Wang, DaQuan
    Chu, Chu
    Zhou, Rui
    Chen, NaiBin
    Ai, XinLei
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer
    Yoshino, Reiko
    Imai, Hisao
    Mori, Keita
    Tomizawa, Yoshio
    Takei, Kosuke
    Tomizawa, Mai
    Kaira, Kyoichi
    Yoshii, Akihiro
    Watanabe, Satoru
    Saito, Ryusei
    Yamada, Masanobu
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (03) : 606 - 611
  • [39] Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy
    Chen, Kuifei
    Li, Shuling
    Chen, Meng
    Jin, Zhicheng
    Sun, Xuefeng
    Zhou, Suna
    Yang, Haihua
    BMC CANCER, 2024, 24 (01)
  • [40] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Hiroaki Akamatsu
    Keita Mori
    Tateaki Naito
    Hisao Imai
    Akira Ono
    Takehito Shukuya
    Tetsuhiko Taira
    Hirotsugu Kenmotsu
    Haruyasu Murakami
    Masahiro Endo
    Hideyuki Harada
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    BMC Cancer, 14